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Objective: To explore and evaluate the most common factors causing therapeutic non-
compliance.
Methods: A qualitative review was undertaken by a literature search of the Medline database 
from 1970 to 2005 to identify studies evaluating the factors contributing to therapeutic 
non-compliance.
Results: A total of 102 articles was retrieved and used in the review from the 2095 articles 
identiﬁ  ed by the literature review process. From the literature review, it would appear that 
the deﬁ  nition of therapeutic compliance is adequately resolved. The preliminary evaluation 
revealed a number of factors that contributed to therapeutic non-compliance. These factors 
could be categorized to patient-centered factors, therapy-related factors, social and economic 
factors, healthcare system factors, and disease factors. For some of these factors, the impact 
on compliance was not unequivocal, but for other factors, the impact was inconsistent and 
contradictory.
Conclusion: There are numerous studies on therapeutic noncompliance over the years. The 
factors related to compliance may be better categorized as “soft” and “hard” factors as the 
approach in countering their effects may differ. The review also highlights that the interaction 
of the various factors has not been studied systematically. Future studies need to address this 
interaction issue, as this may be crucial to reducing the level of non-compliance in general, and 
to enhancing the possibility of achieving the desired healthcare outcomes.
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Introduction
The ultimate aim of any prescribed medical therapy is to achieve certain desired 
outcomes in the patients concerned. These desired outcomes are part and parcel of the 
objectives in the management of the diseases or conditions. However, despite all the 
best intention and efforts on the part of the healthcare professionals, those outcomes 
might not be achievable if the patients are non-compliant. This shortfall may also have 
serious and detrimental effects from the perspective of disease management. Hence, 
therapeutic compliance has been a topic of clinical concern since the 1970s due to the 
widespread nature of non-compliance with therapy. Therapeutic compliance not only 
includes patient compliance with medication but also with diet, exercise, or life style 
changes. In order to evaluate the possible impact of therapeutic non-compliance on 
clinical outcomes, numerous studies using various methods have been conducted in 
the United States (USA), United Kingdom (UK), Australia, Canada and other coun-
tries to evaluate the rate of therapeutic compliance in different diseases and different 
patient populations. Generally speaking, it was estimated that the compliance rate of 
long-term medication therapies was between 40% and 50%. The rate of compliance for 
short-term therapy was much higher at between 70% and 80%, while the compliance 
with lifestyle changes was the lowest at 20%–30% (DiMatteo 1995). Furthermore, the 
rates of non-compliance with different types of treatment also differ greatly. Estimates Therapeutics and Clinical Risk Management 2008:4(1) 270
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showed that almost 50% of the prescription drugs for the 
prevention of bronchial asthma were not taken as prescribed 
(Sabaté 2003). Patients’ compliance with medication therapy 
for hypertension was reported to vary between 50% and 
70% (Sabaté 2003). In one US study, Monane et al found 
that antihypertensive compliance averaged 49%, and only 
23% of the patients had good compliance levels of 80% or 
higher (Monane et al 1996). Among adolescent outpatients 
with cancer, the rate of compliance with medication was 
reported to be 41%, while among teenagers with cancer it 
was higher at between 41% and 53% (Tebbi et al 1986). For 
the management of diabetes, the rate of compliance among 
patients to diet varied from 25% to 65%, and for insulin 
administration was about 20% (Cerkoney and Hart 1980). 
More than 20 studies published in the past few years found 
that compliance with oral medication for type 2 diabetes 
mellitus ranged from 65% to 85% (Rubin 2005). As previ-
ously mentioned, if the patients do not follow or adhere to 
the treatment plan faithfully, the intended beneﬁ  cial effects 
of even the most carefully and scientiﬁ  cally-based treatment 
plan will not be realized. The above examples illustrate the 
extent of the problem of therapeutic non-compliance and why 
it should be a concern to all healthcare providers.
Deﬁ  nition of compliance
To address the issue of therapeutic non-compliance, it is of 
ﬁ  rst and foremost importance to have a clear and acceptable 
deﬁ  nition of compliance. In the Oxford dictionary, compli-
ance is deﬁ  ned as the practice of obeying rules or requests 
made by people in authority (Oxford Advanced Learner’s 
Dictionary of Current English). In healthcare, the most com-
monly used deﬁ  nition of compliance is “patient’s behaviors 
(in terms of taking medication, following diets, or execut-
ing life style changes) coincide with healthcare providers’ 
recommendations for health and medical advice” (Sackett 
1976). Thus, therapeutic non-compliance occurs when an 
individual’s health-seeking or maintenance behavior lacks 
congruence with the recommendations as prescribed by a 
healthcare provider. Other similar terms have been used 
instead of compliance, and the meaning is more or less 
identical. For example, the term adherence is often used 
interchangeably with compliance. Adherence is deﬁ  ned as the 
ability and willingness to abide by a prescribed therapeutic 
regimen (Inkster 2006). Recently, the term “concordance” is 
also suggested to be used. Compared with “compliance”, the 
term concordance makes the patient the decision-maker in 
the process and denotes patients-prescribers agreement and 
harmony (Vermeire et al 2001). Although there are slight and 
subtle differences between these terms, in clinical practice, 
these terms are used interchangeably (albeit may not be 
totally correctly). Therefore, the more commonly used term 
of compliance will be used throughout this article.
Types of non-compliance
After deﬁ  ning what is meant by compliance, the next ques-
tion that comes to mind to the healthcare providers would be: 
“What are the common types of non-compliance encountered 
in clinical medicine?” A knowledge and understanding of the 
various types of non-compliance commonly encountered in 
clinical practice would allow the formulation of strategies to 
tackle them effectively. A review of the literature reveals sev-
eral types of commonly reported or detected non-compliance. 
(Table 1) Besides the types of non-compliance encountered, 
another logical question to ask in trying to complete the 
jigsaw puzzle of therapeutic non-compliance would be: “In 
clinical medicine, what is considered to be good or acceptable 
compliance?” Although it must be acknowledged that this 
is still controversial, in relation to good medication compli-
ance, it has commonly been deﬁ  ned as taking 80 to 120% of 
the medication prescribed (Sackett et al 1975; Monane et al 
1996; Avorn et al 1998; Hope et al 2004). For compliance 
with other treatment such as exercise or diet, the deﬁ  nition 
of acceptable compliance varied among different studies and 
there does not seem to be any commonly accepted criterion 
to deﬁ  ne good or acceptable compliance.
Problems with therapeutic 
non-compliance
Before we can formulate strategies to tackle the issue of 
therapeutic non-compliance, we need to assess the clinical 
and other implications of therapeutic non-compliance.
From the perspective of healthcare providers, therapeutic 
compliance is a major clinical issue for two reasons. Firstly, 
non-compliance could have a major effect on treatment out-
comes and direct clinical consequences. Non-compliance is 
directly associated with poor treatment outcomes in patients 
with diabetes, epilepsy, AIDS (acquired immunodeﬁ  ciency 
syndrome), asthma, tuberculosis, hypertension, and organ 
transplants (Sabaté 2003). In hypertensive patients, poor 
compliance with therapy is the most important reason for 
poorly controlled blood pressure, thus increasing the risk 
of stroke, myocardial infarction, and renal impairment 
markedly. Data from the third NHANES (the National 
Health and Nutrition Examination Survey), which provides 
periodic information on the health of the US population, 
showed that blood pressure was controlled in only 31% of Therapeutics and Clinical Risk Management 2008:4(1) 271
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the hypertension patients between 1999 and 2000 (Hajjar and 
Kotchen 2003). It is likely that non-compliance with treat-
ment contributed to this lack of blood pressure control among 
the general population. For therapeutic non-compliance in 
infectious diseases, the consequences can include not only 
the direct impact such as treatment failures, but also indirect 
impact or negative externalities as well via the development 
of resistant microorganisms (Sanson-Fisher et al 1992). In 
addition, it has been shown that almost all patients who had 
poor compliance with drugs eventually dropped out of treat-
ments completely, and therefore did not beneﬁ  t at all from 
the treatment effects (Lim and Ngah 1991).
Besides undesirable impact on clinical outcomes, non-
compliance would also cause an increased ﬁ  nancial burden 
for society. For example, therapeutic non-compliance has been 
associated with excess urgent care visits, hospitalizations and 
higher treatment costs (Bond and Hussar 1991, Svarstad et al 
2001). It has been estimated that 25% of hospital admissions 
in Australia, and 33%–69% of medication-related hospital 
admissions in the USA were due to non-compliance with 
treatment regimens (Sanson-Fisher et al 1992; Osterberg and 
Blaschke 2005). Additionally, besides direct ﬁ  nancial impact, 
therapeutic non-compliance would have indirect cost implica-
tions due to the loss of productivity, without even mentioning 
the substantial negative effect on patient’s quality of life.
Furthermore, as a result of undetected or unreported thera-
peutic non-compliance, physicians may change the regimen, 
which may increase the cost or complexity of the treatment, 
thus further increasing the burden on the healthcare system. 
The cost burden has been estimated at US$100 billion each 
year in the USA alone (Vermeire et al 2001). Prescription 
drug cost is the fastest growing component of healthcare 
costs in the USA. National outpatient drug spending has 
increased by 13 to 16% per year during the past few years, 
and it is expected to continue to grow by 9%–13% per year 
during the coming decade (Sokol et al 2005). In the era where 
cost-effectiveness is a buzz word in healthcare delivery, any 
factors that could contribute to increased drug use should be 
a concern for the healthcare providers.
Hence, from both the perspective of achieving desirable 
clinical and economic outcomes, the negative effect of thera-
peutic non-compliance needs to be minimized. However, in 
order to formulate effective strategies to contain the problem 
of non-compliance, there is a need to systematically review 
the factors that contribute to non-compliance. An understand-
ing of the predictive value of these factors on non-compliance 
would also contribute positively to the overall planning of 
any disease management program.
Objectives
To conduct a systematic qualitative review to identify the 
most common factors causing therapeutic non-compliance 
from the patient’s perspective.
Methods
Literature searches were undertaken through the Medline 
database from 1970 to 2005. The following MeSH (medical 
subject heading) terms were used: treatment refusal, patient 
compliance, and patient dropouts. MeSH terms provide a 
consistent way to retrieve information that may use different 
terminology for the same concepts. Besides MeSH terms, 
the following key words were also searched in the title or 
abstract: factors, predictors and determinants.
Only English-language journal articles with abstracts 
were included. The populations were adolescents aged 13–18 
years and adults aged 19 years or older. Clinical trials were 
excluded since they were carried out under close monitoring 
and therefore the compliance rates reported would not be 
generalizable. Articles which were categorized by Medline 
Table 1 Type of reported non-compliance
Type of non-compliance   Reference 
Receiving a prescription but not ﬁ  lling it  Donovan and Blake 1992
Taking an incorrect dose 
Taking medication at the wrong times
Increasing or decreasing the frequency of doses
Stopping the treatment too soon
Delaying in seeking healthcare  Vermeire et al 2001
Non-participation in clinic visits
Failure to follow doctor’s instructions  Gordis 1979 
“Drug holidays”, which means the patient stops the therapy for a while  Cummings et al 1982; Vermeire 2001
and then restarts the therapy
“White-coat compliance”, which means patients are compliant to the  Cramer et al 1990; Feinstein 1990; Vermeire 2001;
medication regimen around the time of clinic appointments  Burnier et al 2003Therapeutics and Clinical Risk Management 2008:4(1) 272
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in subsets on AIDS, bioethics, history of medicine, space life 
sciences and toxicology were not included as well.
Abstracts of identiﬁ  ed articles were retrieved manually to 
select original studies and reviews which mainly focused on the 
topics of interest. The topics of interest in the ﬁ  eld of patient 
compliance were: factors that inﬂ  uence therapeutic non-
compliance and the extent of non-compliance with treatment. 
Only non-compliance studies from the patient’s perspective 
were selected. Original studies that included fewer than 50 
patients were eliminated because of inadequate sample size. 
If the sample population of studies was very speciﬁ  c, such as 
involving only males or females, or recruiting patients from 
one speciﬁ  c class (homeless, prisoners or workers from one 
employer, etc), they were eliminated as well because results 
from these studies might not be generalizable to the general 
population. In addition, a number of articles were excluded if 
they mainly focused on strategies to enhance patient’s compli-
ance, methods to measure compliance, validating instruments 
to identify factors inﬂ  uencing non-compliance and the effect of 
non-compliance. When the abstracts were not clear enough to 
decide whether articles met the inclusion criteria, full articles 
were read to make the decision.
Results
A total of 2095 articles were retrieved in this process, and 
after the culling process, 102 articles met the inclusion cri-
teria. The rest were excluded for the reasons such as small 
sample size, not focused on factors affecting compliance, 
not from patients’ perspective, etc (Figure 1). The impact 
of these factors on therapeutic non-compliance would be 
discussed in details in the subsequent sections.
Factors identiﬁ  ed
The factors identiﬁ  ed from the studies and reviews may be 
grouped into several categories, namely, patient-centered 
factors, therapy-related factors, healthcare system factors, 
social and economic factors, and disease factors (Table 2).
Patient-centered factors
Demographic factors
Factors identiﬁ  ed to be in this group include patient’s age, 
ethnicity, gender, education, and marital status. A summary 
of the impact of these factors on therapeutic compliance is 
presented (Table 3).
Age
More than thirty retrieved articles were related to this factor. 
The majority of the studies showed that age was related to 
compliance, although a few researchers found age not to be 
a factor causing non-compliance (Lorenc and Branthwaite 
1993; Menzies et al 1993; Wild et al 2004; Wai et al 2005). 
From a review of the articles showing a correlation between 
age and non-compliance, it would appear that the effect of 
age could be divided into 3 major groups: the elderly group 
(over 55 years old), the middle-age group (40 to 54 years 
old) and the young group (under 40 years old).
For elderly people, the results from the various studies 
are not unidirectional. A large proportion of retrieved studies 
suggested that they might have higher compliance (Norman 
et al 1985; Didlake et al 1988; Schweizer et al 1990; Shea 
et al 1992; Frazier et al 1994; McLane et al 1995; Shaw et al 
1995; Monane et al 1996; Buck et al 1997; Viller et al 1999; 
Sirey et al 2001; Kim et al 2002; Senior et al 2004; Hertz et al 
2005). In a study carried out in UK, patients over 60 years 
old were more likely to be always compliant with their anti-
epileptic tablets than patients under 60 years old (86% vs 
66%, respectively) (Buck et al 1997). It was also suggested 
that patients’ antidepressant drug compliance was positively 
related to age over 60 years (Sirey et al 2001). These results 
are consistent with the conclusion from another published 
review (Krousel-Wood et al 2004). In addition, four studies 
focusing on younger people (mean age 46–50 yr) indicated 
the same trend that compliance increased with the increas-
ing age (Degoulet et al 1983; Christensen and Smith 1995; 
Caspard et al 2005; Lacasse et al 2005).
However, some studies found that advancing age affected 
compliance among elderly people in the opposite direction 
(Okuno et al 1999; Benner et al 2002; Balbay et al 2005). 
Nevertheless, there were confounding factors in these stud-
ies. The study by Balbay et al was carried out in a rural area 
of Turkey among patients with tuberculosis and found that 
younger patients were more compliant to treatment than older 
patients (mean age 42 yr vs 50 yr) (Balbay et al 2005). The 
researchers stated that this might be due to the low education 
level of older patients. Similarly, the study by Okuno et al 
suggested that home-care patients aged 80 and over were less 
likely to be compliant with their prescribed medication, but 
the participants in that particular study had physical disabili-
ties which limit its generalizability (Okuno et al 1999).
Several studies also attempted to venture plausible rea-
sons for poorer compliance among elderly patients. Elderly 
patients may have problems in vision, hearing and memory. 
In addition, they may have more difﬁ  culties in following 
therapy instructions due to cognitive impairment or other 
physical difﬁ  culties, such as having problems in swallowing 
tablets, opening drug containers, handling small tablets, Therapeutics and Clinical Risk Management 2008:4(1) 273
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distinguishing colors or identifying markings on drugs. 
(Murray et al 1986; Stewart and Caranasos 1989; Chizzola 
et al 1996; Nikolaus et al 1996; Okuno et al 2001; Benner et al 
2002; Jeste et al 2003; Cooper et al 2005). On the contrary, 
older people might also have more concern about their health 
than younger patients, so that older patients’ non-compliance 
is non-intentional in most cases. As a result, if they can get the 
necessary help from healthcare providers or family members, 
they may be more likely to be compliant with therapies.
In comparison, the impact of younger age on compliance 
is much more congruent among the studies. Middle-aged 
patients were less likely to be compliant to therapy. In Japan, 
patients in the prime of their life (40–59 years) were found 
less likely to be compliant to the medication (Iihara et al 
2004). Similarly, young patients under 40 years also have a 
low compliance rate (Neeleman and Mikhail 1997; Leggat 
et al 1998; Loong 1999; Siegal and Greenstein 1999). In 
Singapore, patients less than 30 years old were found to be 
less likely to collect the medication prescribed at a polyclinic 
(Loong 1999). In a study about patients’ compliance with 
hemodialysis, patients aged 20 to 39 years were poorly com-
pliant (Leggat et al 1998). Patients in these two age ranges 
(middle-aged patients and young patients under 40 years 
old) always have other priorities in their daily life. Due to 
4590
English, humans, with abstracts,
Published between 1970 to 2005
3453
Age group:
13-18yr and 19yr or older
Not subsets onAIDS, bioethics, history of
medicine, space life sciences and toxicology.
Not clinical trials (1247 were excluded)
111 Reviews were excluded
2095
102
Reviewed titles and abstracts manually
Figure 1 Retrieval and culling process of the articles in literature review process.Therapeutics and Clinical Risk Management 2008:4(1) 274
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their work and other commitments, they may not be able to 
attend to treatment or spend a long time waiting for clinic 
appointments.
  Likewise, low compliance also occurs in adoles-
cents and children with chronic disease (Buck et al 1997; 
Kyngas 1999). Very young children need more help from 
their parents or guardians to implement treatment. Therefore, 
their poorer compliance may be due to a lack of understand-
ing or other factors relating to their parents or guardians. 
For adolescents, this period is often marked by rebellious 
behavior and disagreement with parents and authorities 
(Tebbi 1993). They usually would prefer to live a normal 
life like their friends. This priority could therefore inﬂ  uence 
their compliance.
Ethnicity
Race as a factor causing non-compliance has been studied 
fairly widely in the USA and European countries and sixteen 
studies on this factor were retrieved. Caucasians are believed 
to have good compliance according to some studies (Didlake 
et al 1988; Sharkness and Snow 1992; Turner et al 1995; 
Raiz et al 1999; Thomas et al 2001; Yu et al 2005), while 
African-Americans, Hispanics and other minorities were 
found to have comparatively poor compliance (Schweizer 
et al 1990; Monane et al 1996; Leggat et al 1998; Benner et al 
2002; Apter et al 2003; Opolka et al 2003; Spikmans et al 
2003; Butterworth et al 2004; Kaplan et al 2004; Dominick 
et al 2005). However, a plausible explanation for this may be 
due to patient’s lower socio-economic status and language 
barriers of the minority races in the study countries. Hence, 
due to these confounding variables, ethnicity may not be a 
true predictive factor of poorer compliance.
Gender
In the twenty-two studies retrieved related to this factor, 
the results are contradictory. Female patients were found by 
some researchers to have better compliance (Degoulet et al 
1983; Chuah 1991; Shea et al 1992; Kyngas and Lahden-
pera 1999; Viller et al 1999; Kiortsis et al 2000; Lindberg 
et al 2001; Balbay et al 2005; Choi-Kwon 2005; Fodor 
et al 2005; Lertmaharit et al 2005), while some studies 
suggested otherwise (Frazier et al 1994; Sung et al 1998; 
Caspard et al 2005; Hertz et al 2005). In addition, some 
studies could not ﬁ  nd a relationship between gender and 
compliance (Menzies et al 1993; Buck et al 1997; Horne 
and Weinman 1999; Ghods and Nasrollahzadeh 2003; 
Spikmans et al 2003; Senior et al 2004). This is consistent 
with another literature review on compliance in seniors 
Table2 Categories of factors identiﬁ  ed from the literature review
Category Factors 
Patient-centered factors   Demographic Factors: Age, Ethnicity, Gender, Education, Marriage Status
  Psychosocial factors: Beliefs, Motivation, Attitude
  Patient-prescriber relationship
  Health literacy
  Patient knowledge
  Physical difﬁ  culties
  Tobacco Smoking or alcohol intake
  Forgetfulness
  History of good compliance
Therapy-related factors   Route of administration
  Treatment complexity
  Duration of the treatment period
  Medication side effects
  Degree of behavioral change required
  Taste of the medication
  Requirements for drug storage 
Healthcare system factors   Lack of accessibility
  Long waiting time
  Difﬁ  culty in getting prescriptions ﬁ  lled
  Unhappy clinic visits
Social and economic factors   Inability to take time off work
  Cost and Income
  Social support
Disease factors   Disease symptoms
  Severity of the disease Therapeutics and Clinical Risk Management 2008:4(1) 275
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Table 3 The effect of demographic factors on compliance
Factor   Reference 
  Increased compliance   Decreased compliance   No effect
Age (elderly)   Norman et al 1985;   Okuno et al 1999;  Lorenc and Branthwaite
  Didlake et al 1988;   Benner et al 2002;   1993; 
  Schweizer et al 1990;  Balbay et al 2005  Menzies et al 1993;
  Shea et al 1992;    Wild et al 2004; 
  Frazier et al 1994;     Wai et al 2005 
  McLane et al 1995;    
  Shaw et al 1995;    
  Monane et al 1996;    
  Buck et al 1997;    
  Viller et al 1999;    
  Sirey et al 2001;    
  Kim et al 2002;   
  Senior et al 2004;    
  Hertz et al 2005   
Age (middle-aged)     Iihara et al 2004  
Age (young)     Buck et al 1997; 
    Neeleman and Mikhail 1997; 
    Leggat et al 1998;
   Kyngas  1999;
   Loong  1999;
    Siegal and Greenstein 1999 
Ethnicity  Caucasian   Didlake et al 1988;   
  Sharkness and Snow 1992;     
  Turner et al 1995; Raiz et al 1999;     
  Thomas et al 2001; Yu et al 2005     
  Minorities       Schweizer et al 1990; 
      Monane et al 1996;  
      Leggat et al 1998;  
      Benner et al 2002;  
      Apter et al 2003;  
      Opolka et al 2003; 
      Spikmans et al 2003;
      Butterworth et al 2004; 
      Kaplan et al 2004; 
      Dominick et al 2005
Gender (female)   Degoulet et al 1983;   Frazier et al 1994;   Menzies et al 1993; 
  Chuah 1991; Shea et al 1992;  Sung et al 1998;   Buck et al 1997; 
  Kyngas and Lahdenpera 1999;  Caspard et al 2005;  Horne and Weinman 1999;
  Viller et al 1999;   Hertz et al 2005  Ghods and Nasrollahzadeh 2003;
  Kiortsis et al 2000;     Spikmans et al 2003;
  Lindberg et al 2001;     Senior et al 2004
  Balbay et al 2005;    
 Choi-Kwon  2005;     
  Fodor et al 2005;    
  Lertmaharit et al 2005    
Education level  Apter et al 1998;   Kyngas and Lahdenpera   Norman et al 1985; 
(higher)  Okuno et al 2001;   1999;   Horne and Weinman 1999; 
  Ghods and Nasrollahzadeh 2003;  Senior et al 2004   Spikmans et al 2003; 
  Yavuz et al 2004    Kaona et al 2004; 
      Stilley et al 2004; 
      Wai et al 2005 
Marital status   Swett and Noones 1989;     Spikmans et al 2003; 
(married)   Frazier et al 1994;     Ghods and Nasrollahzadeh 2003;
  De Geest et al 1995;     Kaona et al 2004;
  Turner et al 1995;     Wild et al 2004;
  Cooper et al 2005     Yavuz et al 2004Therapeutics and Clinical Risk Management 2008:4(1) 276
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that concluded that gender has not been found to inﬂ  uence 
compliance (Vic et al 2004). Gender may not be a good 
predictor of non-compliance because of the inconsistent 
conclusions.
Educational level
The effect of educational level on non-compliance was 
equivocal after reviewing thirteen articles which focused 
on the impact of educational level as they used differ-
ent criteria for “higher” and “lower” education. Several 
studies found that patients with higher educational level 
might have higher compliance (Apter et al 1998; Okuno 
et al 2001; Ghods and Nasrollahzadeh 2003; Yavuz et al 
2004), while some studies found no association (Norman 
et al 1985; Horne and Weinman 1999; Spikmans et al 
2003; Kaona et al 2004; Stilley et al 2004; Wai et al 
2005). Intuitively, it may be expected that patients with 
higher educational level should have better knowledge 
about the disease and therapy and therefore be more 
compliant. However, DiMatteo found that even highly 
educated patients may not understand their conditions 
or believe in the benefits of being compliant to their 
medication regimen (DiMatteo 1995). Other researchers 
showed that patients with lower education level have 
better compliance (Kyngas and Lahdenpera 1999; Senior 
et al 2004). A UK study group found that patients without 
formal educational qualifications had better compliance 
with cholesterol-lowering medication (Senior et al 2004). 
Patients with lower educational level might have more 
trust in physicians’ advice. From these results, it seems 
that educational level may not be a good predictor of 
therapeutic compliance.
Marital status
Marital status might inﬂ  uence patients’ compliance with 
medication positively (Swett and Noones 1989; Frazier 
et al 1994; De Geest et al 1995; Turner et al 1995; Cooper 
et al 2005). The help and support from a spouse could be 
the reason why married patients were more compliant to 
medication than single patients. However, marital status 
was not found to be related to patient’s compliance in ﬁ  ve 
recent studies (Ghods and Nasrollahzadeh 2003; Spikmans 
et al 2003; Kaona et al 2004; Wild et al 2004; Yavuz et al 
2004). This disparity might be due to the fact that the recent 
studies investigated the effect of marital status in disease 
conditions which were different from those evaluated in the 
older studies, with the impact being masked by the disease 
factor.
Psychological factors
Patient’s beliefs, motivation and negative attitude towards therapy 
were identiﬁ  ed as factors to be included in this category.
Patients’ beliefs and motivation about the therapy
Twenty-three articles were identiﬁ  ed for this factor in the 
review process. From the results, patients’ beliefs about 
the causes and meaning of illness, and motivation to follow 
the therapy were strongly related to their compliance with 
healthcare (Lim and Ngah 1991; Buck et al 1997; Cochrane 
et al 1999; Kyngas 1999; Kyngas 2001; Kyngas and Rissanen 
2001; Vincze et al 2004).
In summarizing the ﬁ  ndings from the various studies, it 
would appear that compliance was better when the patient 
had the following beliefs:
   The patient feels susceptible to the illness or its compli-
cation (Haynes et al 1980; Abbott et al 1996; Spikmans 
et al 2003).
   The patient believes that the illness or its complications 
could pose severe consequences for his health (McLane 
et al 1995; Sirey et al 2001; Lofﬂ  er et al 2003).
   The patient believes that the therapy will be effective 
or perceives benefits from the therapy (Lorenc and 
Branthwaite 1993; De Geest et al 1995; Cochrane et al 
1999; Horne and Weinman 1999; Apter et al 2003; 
Spikmans et al 2003; Krousel-Wood et al 2004; Wild 
et al 2004; Gonzalez et al 2005; Seo and Min 2005).
On the contrary, misconceptions or erroneous beliefs held 
by patients would contribute to poor compliance. Patient’s 
worries about the treatment, believing that the disease is 
uncontrollable and religious belief might add to the likeli-
hood that they are not compliant to therapy. In a review to 
identify patient’s barriers to asthma treatment compliance, 
it was suggested that if the patients were worried about 
diminishing effectiveness of medication over time, they were 
likely to have poor compliance with the therapy (Bender 
and Bender 2005). In patients with chronic disease, the 
fear of dependence on the long-term medication might be a 
negative contributing factor to compliance (Apter et al 2003; 
Bender and Bender 2005). This is sometimes augmented 
further by cultural beliefs. For example, in Malaysia, some 
hypertension patients believed long-term use of “Western” 
medication was “harmful”, and they were more conﬁ  dent in 
herbal or natural remedies (Lim and Ngah 1991). In a New 
Zealand study, Tongan patients may think disease is God’s 
will and uncontrollable; and as a consequence, they perceived 
less need for medication (Barnes et al 2004). Similarly, in 
Pakistan, inbred fears and supernatural beliefs were reported Therapeutics and Clinical Risk Management 2008:4(1) 277
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to be two major factors affecting patients’ compliance with 
treatment (Sloan and Sloan 1981).
Patients who had low motivation to change behaviors or 
take medication are believed to have poor compliance (Lim 
and Ngah 1991; Hernandez-Ronquillo et al 2003; Spikmans 
et al 2003). In a study done in Malaysia, 85% of hypertension 
patients cited lack of motivation as the reason for dropping 
out of treatment (Lim and Ngah 1991).
Negative attitude towards therapy
Fifteen studies showed an association between patients’ 
negative attitude towards therapy (eg, depression, anxiety, 
fears or anger about the illness) and their compliance (Lorenc 
and Branthwaite 1993; Bosley et al 1995; Carney et al 1995; 
Milas et al 1995; Jette et al 1998; Clark et al 1999; Raiz 
et al 1999; Sirey et al 2001; Barnes et al 2004; Gascon et al 
2004; Iihara et al 2004; Kaplan et al 2004; Stilley et al 2004; 
Kilbourne et al 2005; Yu et al 2005). In one study conducted 
in patients older than 65 years with coronary artery disease, 
depression affected compliance markedly (Carney et al 
1995). There were other studies reporting that for children 
or adolescents, treatment may make them feel stigmatized 
(Bender and Bender 2005), or feel pressure because they 
are not as normal as their friends or classmates (Kyngas 
1999). Therefore, negative attitude towards therapy should 
be viewed as a strong predictor of poor compliance.
Patient-prescriber relationship
Seventeen articles evaluated the effect of the patient-
prescriber relationship to patient’s compliance. From these 
articles it could be concluded that patient-prescriber relation-
ship is another strong factor which affects patients’ compli-
ance (Buck et al 1997; Roter and Hall 1998; Stromberg et al 
1999; Kiortsis et al 2000; Okuno et al 2001; Kim et al 2002; 
Lofﬂ  er et al 2003; Moore et al 2004; Gonzalez et al 2005). 
A healthy relationship is based on patients’ trust in prescrib-
ers and empathy from the prescribers. Studies have found 
that compliance is good when doctors are emotionally sup-
portive, giving reassurance or respect, and treating patients 
as an equal partner (Moore et al 2004; Lawson et al 2005). 
Rubin mentioned some situations that may inﬂ  uence patients’ 
trust in physicians (Rubin 2005). For example, physicians 
who asked few questions and seldom made eye contact with 
patients, and patients who found it difﬁ  cult to understand the 
physician’s language or writing. More importantly, too little 
time spent with patients was also likely to threaten patient’s 
motivation for maintaining therapy (Lim and Ngah 1991; 
Gascon et al 2004; Moore et al 2004; Lawson et al 2005).
Poor communication with healthcare providers was also 
likely to cause a negative effect on patient’s compliance 
(Bartlett et al 1984; Apter et al 1998). Lim and Ngah showed 
in their study that non-compliant hypertension patients 
felt the doctors were lacking concern for their problems 
(Lim and Ngah 1991). In addition, multiple physicians or 
healthcare providers prescribing medications might decrease 
patients’ conﬁ  dence in the prescribed treatment (Vlasnik 
et al 2005).
These ﬁ  ndings demonstrate the need for cooperation 
between patients and healthcare providers and the impor-
tance of good communication. To build a good and healthy 
relationship between patients and providers, providers should 
have patients involved in designing their treatment plan 
(Gonzalez et al 2005; Vlasnik et al 2005), and give patients 
a detailed explanation about the disease and treatment 
(Butterworth et al 2004; Gascon et al 2004). Good communi-
cation is also very important to help patients understand their 
condition and therapy (Lorenc and Branthwaite 1993).
Health literacy
Health literacy means patients are able to read, understand, 
remember medication instructions, and act on health infor-
mation (Vlasnik et al 2005). Patients with low health lit-
eracy were reported to be less compliant with their therapy 
(Nichols-English and Poirier 2000). On the contrary, patients 
who can read and understand drug labels were found to be 
more likely to have good compliance (Murray et al 1986; 
Lorenc and Branthwaite 1993; Butterworth et al 2004). Thus, 
using written instructions and pictograms on medicine labels 
has proven to be effective in improving patient’s compliance 
(Dowse and Ehlers 2005; Segador et al 2005).
Patient knowledge
Patient’s knowledge about their disease and treatment is 
not always adequate. Some patients lack understanding of 
the role their therapies play in the treatment (Ponnusankar 
et al 2004); others lack knowledge about the disease and 
consequences of poor compliance (Alm-Roijer et al 2004; 
Gascon et al 2004); or lack understanding of the value of 
clinic visits (Lawson et al 2005). Some patients thought 
the need for medication was intermittent, so they stopped 
the drug to see whether medication was still needed (Vic 
et al 2004; Bender and Bender 2005). For these reasons, 
patient education is very important to enhance compliance. 
Counseling about medications is very useful in improving 
patient’s compliance (Ponnusankar et al 2004). Healthcare 
providers should give patients enough education about the Therapeutics and Clinical Risk Management 2008:4(1) 278
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treatment and disease (Haynes et al 1980; Norman et al 1985; 
Stanton 1987; Olubodun et al 1990; Lorenc and Branthwaite 
1993; Menzies et al 1993; Milas et al 1995; Chizzola et al 
1996; Hungin 1999; Liam et al 1999; Okuno et al 1999; 
Viller et al 1999; Lindberg et al 2001; Thomas et al 2001; 
Gascon et al 2004; Iihara et al 2004; Kaona et al 2004; 
Ponnusankar et al 2004; Seo and Min 2005).
However, education is not always “the more the bet-
ter”. An “inverted U” relationship between knowledge and 
compliance existed in adolescents. Adolescent patients who 
knew very little about their therapies and illness were poor 
compliers, while patients who were adequately educated 
about their disease and drug regimens were good compliers; 
but patients who knew the life-long consequences might show 
poor compliance (Hamburg and Inoff 1982). Nevertheless, 
there is no report of similar observations in other age groups. 
In addition, patients’ detailed knowledge of the disease was 
not always effective. In Hong Kong, researchers could not 
ﬁ  nd any association between diabetes knowledge and com-
pliance. They suggested that there was a gap between what 
the patients were taught and what they were actually doing 
(Chan and Molassiotis 1999).
In addition, the content of education is crucial. Rubin 
found that educating the patients about their disease state 
and general comprehension of medications would increase 
their active participation in treatment (Rubin 2005). Making 
sure patients understand the drug dosing regimen could also 
improve compliance (Olubodun et al 1990). To make sure 
patients remember what was taught, written instructions work 
better than verbal ones, as patients often forget physician’s 
advice and statements easily (Tebbi 1993).
Other factors
Smoking or alcohol intake
Several studies about compliance among asthma, hyperten-
sion and renal transplantation patients found that patients 
who smoked or drank alcohol were more likely to be non-
compliant (Degoulet et al 1983; Shea et al 1992; Turner 
et al 1995; Leggat et al 1998; Kyngas 1999; Kyngas and 
Lahdenpera 1999; Kiortsis et al 2000; Kim et al 2002; 
Ghods and Nasrollahzadeh 2003; Yavuz et al 2004; Balbay 
et al 2005; Cooper et al 2005; Fodor et al 2005). In a study 
conducted in Finland in hypertension patients, non-smokers 
were more compliant to the diet restrictions (Kyngas and 
Lahdenpera 1999). Likewise, another study in renal trans-
plantation patients in Turkey found that patients who were 
smoking or drinking were unlikely to be compliant to the 
therapy (Yavuz et al 2004). Only one single study about 
obstructive sleep apnoea/hypopnoea syndrome (OSAHS) 
found no relationship between smoking or alcohol intake 
and patient’s compliance with continuous positive airway 
pressure treatment (Wild et al 2004).
Forgetfulness
Forgetfulness is a widely reported factor that causes 
non-compliance with medication or clinic appointments 
(Cummings et al 1982; Kelloway et al 1994; Okuno et al 
2001; Hernandez-Ronquillo et al 2003; Ponnusankar et al 
2004; Wai et al 2005). A Japanese study in elderly home-care 
recipients found an interesting association between meal fre-
quency and compliance. Patients having less than 3 meals per 
day were less compliant than patients having 3 meals a day. It 
suggested that meal frequency was an effective tool to remind 
the patient to take drugs (Okuno et al 1999). As mentioned 
in a previous section, written instructions are better than oral 
advice for reminding patients to take medication.
Therapy-related factors
Therapy-related factors identiﬁ  ed include: route of admin-
istration, treatment complexity, duration of treatment 
period, medication side effects, degree of behavioral change 
required, taste of medication and requirement for drug stor-
age (Table 4).
Route of administration
Medications with a convenient way of administration (eg, 
oral medication) are likely to make patients compliant. 
Studies in asthma patients compared compliance between 
oral and inhaled asthma medications, and found patients 
had better compliance with oral medication (Kelloway et al 
1994; Nichols-English and Poirier 2000). Likewise, difﬁ  culty 
in using inhalers contributes to non-compliance in patients 
with asthma (Bender and Bender 2005).
Treatment complexity
Complex treatment is believed to threaten the patient’s compli-
ance. However, compliance does not seem to correlate with the 
number of drugs prescribed (Horne and Weinman 1999; Patal 
and Taylor 2002; Grant et al 2003; Iihara et al 2004), but the 
number of dosing times every day of all prescribed medications 
(Kass et al 1986; Cockburn et al 1987; Cramer et al 1989; Eisen 
et al 1990; Cramer 1998; Sung et al 1998; Claxton et al 2001; 
Iskedjian et al 2002). The rate of compliance decreased as the 
number of daily doses increased. This is illustrated by one study 
where compliance was assessed by pill counts and self-reports 
that showed that non-compliance increased with an increase in 
the frequency of prescribed dosing: 20% for once daily; 30% Therapeutics and Clinical Risk Management 2008:4(1) 279
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for twice daily; 60% for three times a day; and 70% for four 
times daily (Cramer et al 1989). Similarly, a meta-analysis 
found that there was a signiﬁ  cant difference in compliance rate 
between patients taking antihypertensive medication once daily 
and twice daily (92.1% and 88.9%, respectively) (Iskedjian et al 
2002). Thus, simplifying the medication dosing frequency could 
improve compliance markedly.
Duration of the treatment period
Acute illnesses are associated with higher compliance than 
chronic illnesses (Gascon et al 2004). In addition, longer 
duration of the disease may adversely affect compliance 
(Farmer et al 1994; Frazier et al 1994). Similarly, a longer 
duration of treatment period might also compromise patient’s 
compliance (Menzies et al 1993; Ghods and Nasrollahzadeh 
Table 4 The effect of therapy-related factors on compliance
Factor Reference 
  Increased compliance   Decreased compliance  No effect 
Convenient route of  Kelloway et al 1994;
medication administration  Nichols-English and Poirier 2000   
Increasing number of  Buck et al 1997;  Murray et al 1986;  Horne and Weinman 1999;
medications taken  Fodor et al 2005   Kiortsis et al 2000  Patal and Taylor 2002;
      Grant et al 2003;
      Iihara et al 2004
Increasing number of     Kass et al 1986;  
dosing times     Cockburn et al 1987; 
    Cramer et al 1989;
    Eisen et al 1990;  
    Cramer 1998;  
    Sung et al 1998;  
    Claxton et al 2001;
    Iskedjian et al 2002  
Long duration of  Sharkness and Snow 1992;  International Union Against
treatment period  Garay-Sevilla et al 1995  Tuberculosis 1982; 
    Combs et al 1987; 
    Menzies et al 1993;
    Farmer et al 1994;
    Frazier et al 1994;  
    Ghods and Nasrollahzadeh 2003;
    Gascon et al 2004;  
    Dhanireddy et al 2005 
Medication side effect     Spagnoli et al 1989;
    Shaw et al 1995;
    Buck et al 1997; 
    Dusing et al 1998;
   Hungin  1999;
    Kiortsis et al 2000;
    Linden et al 2000;
    Kim et al 2002;
    Dietrich et al 2003;
    Grant et al 2003; 
   Lofﬂ  er et al 2003; 
    Sleath et al 2003; 
    Iihara et al 2004; 
    Kaplan et al 2004;
    Ponnusankar et al 2004;
   O’Donoghue  2004 
High degree of behavior     Milas et al 1995; 
changed required     Hernandez-Ronquillo et al 2003;
    Vincze et al 2004
Bad taste of the medication     O’Donoghue 2004
Inconvenient requirement     O’Donoghue 2004
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2003; Dhanireddy et al 2005). In one trial that compared 
6-month and 9-month treatment of tuberculosis, compliance 
rates were 60% and 50% for the two regimens, respectively 
(Combs et al 1987). In another study comparing preventive 
regimens of 3, 6 and 12 months, compliance rates were 87%, 
78% and 68% for the three regimens, respectively (Interna-
tional Union Against Tuberculosis 1982).
However, some studies about chronic diseases found 
that longer duration of the disease resulted in good compli-
ance (Sharkness and Snow 1992; Garay-Sevilla et al 1995), 
and newly diagnosed patients had poor compliance (Caro 
et al 1999). This may indicate that compliance is improved 
because patient’s attitude of denying the disease is reduced 
and they accepted treatment after years of suffering from 
the disease.
Medication side effects
All of the seventeen studies on side effects factor found that 
side effects threaten patient’s compliance (Spagnoli et al 
1989; Shaw et al 1995; Buck et al 1997; Dusing et al 1998; 
Hungin 1999; Kiortsis et al 2000; Linden et al 2000; Kim 
et al 2002; Dietrich et al 2003; Grant et al 2003; Lofﬂ  er et al 
2003; Sleath et al 2003; Iihara et al 2004; Kaplan et al 2004; 
Ponnusankar et al 2004; O’Donoghue 2004). In a German 
study, the second most common reason for non-compliance 
with antihypertensive therapy was adverse effects (Dusing 
et al 1998). The effect of side effects on compliance may be 
explained in terms of physical discomfort, skepticism about 
the efﬁ  cacy of the medication, and decreasing the trust in 
physicians (Christensen 1978).
Degree of behavioral change required
The degree of required behavioral change is related to 
patients’ motivation to be compliant with the therapy (Milas 
et al 1995; Hernandez-Ronquillo et al 2003; Vincze et al 
2004). A study done in Mexico demonstrated that patients 
with type 2 diabetes could not follow the diet because of 
the difﬁ  culty of changing their dietary habits (Hernandez-
Ronquillo et al 2003).
Social and economic factors
Social and economic factors include: time commitment, cost 
of therapy, income and social support.
Time commitment
Patients may not be able to take time off work for treatment; 
as a result, their rate of compliance could be threatened (Shaw 
et al 1995; Siegal and Greenstein 1999; Hernandez-Ronquillo 
et al 2003; Lawson et al 2005; Neal et al 2005). Therefore, 
a shorter traveling time between residence and healthcare 
facilities could enhance patient’s compliance (Gonzalez et al 
2005). A study suggested that white collar patients have poor 
compliance because they have other priorities (Siegal and 
Greenstein 1999). Housewives with tuberculosis were more 
compliant to therapy in an observational study in Malaysia 
(Chuah 1991). This may be because housewives can adapt 
well to clinic appointment times and treatment.
Cost of therapy and income
Cost is a crucial issue in patient’s compliance especially for 
patients with chronic disease as the treatment period could 
be life-long (Connelly 1984; Shaw et al 1995; Ellis et al 
2004; Ponnusankar et al 2004). Healthcare expenditure 
could be a large portion of living expenses for patients 
suffering from chronic disease. Cost and income are two 
interrelated factors. Healthcare cost should not be a big 
burden if the patient has a relatively high income or health 
insurance. A number of studies found that patients who had 
no insurance cover (Swett and Noones 1989; Kaplan et al 
2004; Choi-Kwon 2005), or who had low income (Degoulet 
et al 1983; Cockburn et al 1987; Shea et al 1992; Frazier et al 
1994; Apter et al 1998; Berghofer et al 2002; Benner et al 
2002; Ghods and Nasrollahzadeh 2003; Hernandez-Ronquillo 
et al 2003; Mishra et al 2005) were more likely to be non-
compliant to treatment. However, even for patients with 
health insurance, health expenses could still be a problem. 
More than one in ten seniors in the USA reported using less 
of their required medications because of cost (Congressional 
Budget Ofﬁ  ce 2003). Nevertheless, in other cases, income 
was not related to compliance level (Norman et al 1985; Lim 
and Ngah 1991; Patal and Taylor 2002; Stilley et al 2004; 
Wai et al 2005). In Singapore, a study on chronic hepatitis 
B surveillance found that monthly income was not related 
to patient’s compliance with regular surveillance (Wai et al 
2005). This discrepancy might due to different healthcare 
systems in different countries. Healthcare personnel should 
be aware of patient’s economic situation and help them use 
medication more cost-effectively.
Social support
The general ﬁ  ndings from these articles showed that patients 
who had emotional support and help from family members, 
friends or healthcare providers were more likely to be compli-
ant to the treatment (Stanton 1987; Lorenc and Branthwaite 
1993; Garay-Sevilla et al 1995; Milas et al 1995; Kyngas 
1999; Okuno et al 1999; Stromberg et al 1999; Kyngas 2001; 
Kyngas and Rissanen 2001; Thomas et al 2001; Lofﬂ  er et al Therapeutics and Clinical Risk Management 2008:4(1) 281
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2003; DiMatteo 2004; Feinstein et al 2005; Seo and Min 
2005; Voils et al 2005). The social support helps patients in 
reducing negative attitudes to treatment, having motivation 
and remembering to implement the treatment as well.
Healthcare system factors
The main factor identiﬁ  ed relating to healthcare systems 
include availability and accessibility. Lack of accessibility 
to healthcare (Ponnusankar et al 2004), long waiting time 
for clinic visits (Grunebaum et al 1996; Balkrishnan et al 
2003; Moore et al 2004; Lawson et al 2005; Wai et al 2005), 
difﬁ  culty in getting prescriptions ﬁ  lled (Cummings et al 1982; 
Vlasnik et al 2005), and unhappy or unsatisﬁ  ed clinic visits 
(Spikmans et al 2003; Gascon et al 2004; Lawson et al 2005) 
all contributed to poor compliance. The above observation 
is further supported by another study that showed patient’s 
satisfaction with clinic visits is most likely to improve their 
compliance with the treatment (Haynes et al 1980).
Disease factor
Patients who are suffering from diseases with ﬂ  uctuation 
or absence of symptoms (at least at the initial phase), such 
as asthma and hypertension, might have a poor compliance 
(Hungin 1999; Kyngas and Lahdenpera 1999; Vlasnik et al 
2005). Kyngas and Lahdenpera demonstrated that there was 
a signiﬁ  cant relationship between the presence of hyperten-
sion symptoms and reduction in the sodium consumption. 
Seventy-one percent of the patients who had symptoms 
reduced the use of sodium, as compared to only 7% of the 
patients who did not suffer from symptoms (Kyngas and 
Lahdenpera 1999). Patients who had marked improvement 
in symptoms with the help of treatment normally had better 
compliance (Lim et al 1992; Viller et al 1999; Grant et al 
2003).
In addition, no consistent evidence shows that subjects 
with greater disease severity based on clinical evalua-
tion comply better with medications than healthier ones 
(Matthews and Hingson 1977; Kyngas 1999; Wild et al 2004; 
Seo and Min 2005). A study in patients with OSAHS found 
that greater disease severity based on clinical variables pre-
dicted better compliance (Wild et al 2004). However, a study 
on compliance in adolescents with asthma showed that only 
patients with mild severity had good compliance (Kyngas 
1999). Similarly, Matthews et al suggested that the actual 
severity of the illness (based on the physician’s clinical evalu-
ation) was not related to compliance (Matthews and Hingson 
1977). Instead of actual disease severity, perceived health 
status may have more signiﬁ  cant inﬂ  uence on compliance. 
Patients expecting poor health status are more motivated to 
be compliant with treatment if they consider the medication 
to be effective (Rosenstock et al 1988). In a study conducted 
in the USA in patients on antihyperlipidemic medications, 
patients with a perception of poor health status were more 
compliant with treatment (Sung et al 1998). This supports 
the suggestion that how patients feel plays a crucial role in 
predicting compliance.
Discussion
From the literature review, it can be concluded that although 
several terms have been used, the terms are used more or 
less interchangeably in clinical practice and therefore, the 
deﬁ  nition of compliance is adequately deﬁ  ned in the prac-
tical context. However, one alarming observation is that 
non-compliance remains a major issue in enhancing health-
care outcomes in spite of the many studies highlighting the 
problem over the years.
In this review we attempted to identify factors related 
to compliance which would have wide generalizability, and 
we retrieved original studies investigating non-compliance 
from different diseases, population settings and different 
countries. In the process, we identiﬁ  ed a wide array of inﬂ  u-
encing factors. Although some factors’ effect on compliance 
is complex and not unequivocal, several factors with con-
sistent impact on compliance have been identiﬁ  ed through 
the review process.
Firstly, addressing therapy-related factors should 
contribute positively in improving patient’s compliance. 
Prescribing medication with non-invasive route of admin-
istration (eg, oral medication) and simple dosing regimens 
might motivate patients to be compliant. Long duration of 
treatment period and medication side effects might com-
promise patient’s beliefs about medication effectiveness. 
Therefore, healthcare providers should consider therapy-
related problems when designing the therapy plan and 
involve the patients in the process to minimize the possible 
therapeutic barriers.
Besides therapy-related factors, healthcare system prob-
lems were found to be signiﬁ  cantly related to compliance. 
Accessibility and satisfaction with the healthcare facilities 
are important contributors to compliance because patient’s 
satisfaction with healthcare is crucial for their compliance. 
Long waiting time for clinic visits and unhappy experi-
ence during clinic visits was indicated by many studies. 
A healthcare system designed with convenient accessibility 
and patient satisfaction in mind would be a great help for 
compliance issue.Therapeutics and Clinical Risk Management 2008:4(1) 282
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Thirdly, compliance is also related with disease 
characteristics. Non-compliance is usually not a prevalent 
issue in acute illness or illness of short duration. In contrast, 
patients who are suffering from chronic diseases, in particular 
those with ﬂ  uctuation or absence of symptoms (eg, asthma 
and hypertension) are likely to be non-compliant. Special 
efforts and attention should be paid to address the issue of 
non-compliance in chronic disease patients.
Lastly, healthcare expenditure is a very important factor 
for patients with chronic diseases because the treatment 
could be life-long so the cost of therapy would constitute a 
large portion of their disposable income. If the patient feels 
that the cost of therapy is a ﬁ  nancial burden, the compli-
ance with therapy will deﬁ  nitely be threatened. Healthcare 
personnel should be aware of patient’s economic situation 
during the planning of a treatment regimen, and a health-
care ﬁ  nance system that provides at least some ﬁ  nancial 
assistance to low income patients would be helpful to boost 
compliance.
These factors discussed so far are directly and clearly 
related to patient’s compliance. We can call them the “hard” 
factors. We are using this term as the impact of factors 
identiﬁ  ed is more quantiﬁ  able. By and large, these “hard” 
factors are amendable to a certain extent by counseling and 
communication by healthcare providers. In additional, the 
society could also participate in minimizing the barriers for 
patients to follow the therapy.
In contrast with “hard” factors, some other factors might 
be classiﬁ  ed as “soft” factors because their effects are much 
more difﬁ  cult to measure and counter. In fact, a failure to 
address the “soft” factors may negate all efforts spent in 
countering the effects of the “hard” factors.
Psycho-social factors such as patient’s beliefs, attitude 
towards therapy and their motivation to the therapy could 
be classiﬁ  ed as “soft” factors. Since the 1990’s, research 
has focused more on the patient-provider relationship and 
patients’ beliefs about the therapies. For patients with 
chronic diseases, they would do their own cost-beneﬁ  t 
analysis of therapy, either consciously or subconsciously. 
It means they weigh the beneﬁ  ts from compliance with 
therapy (ie, controlling symptoms and preventing medical 
complications) against constraints on their daily lives and 
perceived risks of therapy such as side effects, time and 
effort involved (Donovan and Blake 1992). Sometimes, 
they may have the wrong beliefs based on inadequate health 
knowledge or a negative relationship with the healthcare 
provider. Hence, patients should be given adequate knowl-
edge about the purpose of the therapy and consequences 
of non-compliance. In addition, a healthy relationship and 
effective communication between the patient and healthcare 
provider would enhance patient’s compliance. In fact, the 
effects of patient’s beliefs, health knowledge and relation-
ship with the healthcare provider are very complex because 
these “soft” factors are inter-related with each other. The 
interaction is a bit like antibiotic combinations. Sometimes 
the effect would be additive or synergistic, while other 
times the effect would be antagonistic. However, due to the 
design of the studies performed so far, it is difﬁ  cult, if not 
impossible, to differentiate precisely whether the interac-
tion between these factors would be additive, synergistic 
or antagonistic. More robust and better designed studies 
would be needed in future to elucidate this effect.
Similar to the “soft” factors, the effect of demographic 
factors (eg, age, gender, ethnicity, educational level and 
marital status) on compliance is also rather complicated, 
because they may not be truly independent factors inﬂ  uenc-
ing compliance. Actually, demographic factors are related to 
patient’s various cultural, socioeconomic and psychological 
backgrounds. Thus, future studies on compliance should not 
focus on demographic factors alone.
Deﬁ  nitely, there are some limitations in the current 
review. Firstly, only one electronic database, PubMed, was 
searched and only English articles were included. It might 
be possible that some informative studies in other literature 
databases or in other languages were omitted. Secondly, 
there is a shortcoming in the search strategy in that only 
articles with abstracts were retrieved. There are quite a num-
ber of studies published in 1970s and early 1980s without 
abstracts that were not screened. However, we do believe 
that the review so far has captured most of the key factors 
with potential inﬂ  uence on therapeutic compliance from the 
patient’s perspective.
In conclusion, from the review of the literature starting 
from the 1970s to identify relevant factors relating to therapeu-
tic compliance, the evidence indicates that non-compliance 
is still commonplace in healthcare and no substantial change 
occurred despite the large number of studies attempting to 
address and highlight the problem. In addition, too few studies 
are being done systematically to quantify the impact of non-
compliance on health and ﬁ  nancial outcomes. The magnitude 
of the impact of non-compliance needs to be studied in future 
compliance research due to the potential tremendous implica-
tion of poor compliance on clinical and economic outcomes. 
Finally, few studies on compliance have been performed in 
Asian and developing countries where most of the world’s 
population resides. More studies on factors influencing Therapeutics and Clinical Risk Management 2008:4(1) 283
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compliance in these countries or regions would be helpful 
to ﬁ  ll in the knowledge gap and contribute to formulating 
international strategies for countering non-compliance.
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